Merz Pharma
the complexing-protein-free "naked toxin" BoNT-A, manufactured via Merz's proprietary purification technology that removes accessory proteins during production; approved in 79 countries for therapeutic and aesthetic indications, with EU EMA submission (January 26,…
- Country
- Germany
Japan MHLW cervical dystonia + blepharospasm approval June 19, 2026; EU pediatric spasticity EMA submission Jan 26, 2026
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant botulinum toxin (biosynthetic Botox) | specialty-fine-chem | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.